Veracyte, Inc.

NASDAQ:VCYT

Biotechnology

Healthcare
$25.57 +3.56%

+$1.83 today

Market cap
$2.06B
Beta
1.98
P/E (TTM)
48.0
EPS (TTM)
$1.11
52W Low $22.61High $53.66

Volume 2.45M

Average 1.05M

VCYT Acquisitions (Net)

Cash paid for acquiring businesses, net of cash acquired.

Veracyte, Inc.NASDAQ: VCYT

Acquisitions (Net) · Q2 FY2026 · quarter ended Jun 2026

Acquisitions (net) outflow grows to $0

Q2 FY2026 acquisitions (net) was $0, compared with $0 a year earlier. Trailing-twelve-month acquisitions (net) was -$2.85M.

Context

  • Acquisitions (net) amounted to 0.6% of revenue in FY2025, down 0.6 pp from a year earlier.
  • Acquisitions (net) increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly acquisitions (net) holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$711.25K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
-$2.85M-156.8% YoY
LTMJun 2026
-$2.85M— YoY
Acquisitions (Net) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-156.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Acquisitions (Net) history

USD · from the cash flow

Latest · FY2025
(2.85M) USD
Year-over-year change
-156.8%

Acquisitions (Net) vs competitors

How VCYT compares with its peers on the latest reported figures

  • VCYT's LTM Jun 2026 acquisitions (net) of $2.85M is the 3rd largest of the 10 companies compared; the peer median is $0.
  • Acquisitions (net) amounts to 0.5% of revenue for VCYT, versus a peer median of 0.0%.
VCYT Competitors Peer median
Acquisitions (Net) for VCYT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
WGSGeneDx Holdings Corp.LTM Jun 2026$32.86M —-36.3%7.2%
CSTLCastle Biosciences, Inc.LTM Mar 2026$18.7M —-11.4%5.5%
VCYTVeracyte, Inc.LTM Jun 2026$2.85M ——0.5%
NEONeoGenomics, Inc.LTM Jun 2026$463K -92.3%—0.1%
PSNLPersonalis, Inc.LTM Mar 2026$120K ——0.2%
GHGuardant Health, Inc.LTM Sep 2026$0 ——0.0%
BLLNBillionToOne, Inc.LTM Jun 2026$0 ——0.0%
MYGNMyriad Genetics, Inc.LTM Mar 2026$0 ——0.0%
BDSXBiodesix, Inc.LTM Mar 2026$0 ——0.0%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding VCYT) $0-92.3%-23.9%0.0%

Competitors are the stored peer set for VCYT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(75.56M)(36.56M)(74.4M)24.14M66.35M
Depreciation & Amortization19.59M25.93M27.19M23.46M21.42M
Deferred Income Tax(6.26M)133K(3.84M)(233K)(581K)
Stock-Based Compensation22.52M26.73M33.14M36.25M43.6M
Change in Working Capital4.22M(16.38M)(3.7M)(20.97M)(2.3M)
Accounts Receivables(8.57M)(4.5M)3.89M(6.41M)(708K)
Inventory(1.46M)(3.01M)(1.69M)(5.87M)(2.86M)
Accounts Payables5.16M152K(134K)(4.31M)(1.04M)
Other Working Capital9.1M(9.03M)(5.75M)(4.38M)2.31M
Other Non-Cash Items3.87M7.68M65.83M12.45M7.82M
Operating Cash Flow(31.62M)7.54M44.22M75.1M136.31M
Capital Expenditures(5.38M)(8.55M)(9.96M)(11.29M)(9.68M)
Acquisitions (Net)(736.83M)005.01M(2.85M)
Purchases of Investments162.42M(33.52M)(19.7M)(50M)(150M)
Sales of Investments3M12.68M44.77M0153.31M
Other Investing Activities(162.42M)0000
Investing Cash Flow(739.21M)(29.39M)15.11M(56.28M)(9.21M)
Debt Repayment0(1.28M)000
Common Stock Issued593.82M0019.99M14.08M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.5M4.78M2.84M(15.09M)(18.3M)
Financing Cash Flow596.32M3.49M2.84M4.9M(4.22M)
Effect of Forex Changes(1.51M)(592K)163K(424K)615K
Net Change in Cash(176.02M)(18.95M)62.33M23.3M123.6M
Free Cash Flow(37M)(1.01M)34.26M63.81M126.63M

Veracyte, Inc.

NASDAQ:VCYT

Intrinsic Alpha fair value

Locked

Current Price

$25.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.